Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“Expanding Antibody Therapeutics with TCR Mimicry.
Monoclonal antibody therapies have revolutionized treatment, but their reach is limited to extracellular targets. TCR mimetic (TCRm) antibodies overcome this by recognizing peptide-HLA (pHLA) complexes, unlocking a vast pool of intracellular-derived targets with greater specificity and affinity.
Key Highlights:
- TCRm antibodies extend antibody-based targeting beyond surface proteins
- Comprehensive pipeline integrates mass spectrometry, bioinformatics and cryo-EM
- TCRm CAR T cells demonstrate potent antitumor activity across multiple HLA alleles
This approach could pave the way for next-generation immunotherapies, expanding the potential of antibody-based treatments.”
Authors: Robert Salzler, David J. DiLillo, Kei Saotome, Kevin Bray, Katja Mohrs, Haun Hwang, Kamil J. Cygan, Darshit Shah
